<p>在过去的 7 天里，美国市场下跌了 2.5%，但在过去一年中上涨了 23%，预计未来几年收益将以每年 17% 的速度增长。在这种环境下，识别可能低于其估计价值的股票可以为寻求利用未来增长前景的投资者提供潜在机会。</p>
<h3>基于现金流的美国十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>Solstice Advanced Materials (SOLS)</td>
<td>$81.02</td>
<td>$156.32</td>
<td>48.2%</td>
</tr>
<tr>
<td>Robert Half (RHI)</td>
<td>$31.26</td>
<td>$60.09</td>
<td>48%</td>
</tr>
<tr>
<td>Rayonier (RYN)</td>
<td>$20.97</td>
<td>$40.79</td>
<td>48.6%</td>
</tr>
<tr>
<td>MercadoLibre (MELI)</td>
<td>$1607.80</td>
<td>$3085.44</td>
<td>47.9%</td>
</tr>
<tr>
<td>Live Oak Bancshares (LOB)</td>
<td>$37.41</td>
<td>$74.21</td>
<td>49.6%</td>
</tr>
<tr>
<td>Lazard (LAZ)</td>
<td>$46.36</td>
<td>$91.21</td>
<td>49.2%</td>
</tr>
<tr>
<td>Inter &amp; Co (INTR)</td>
<td>$5.67</td>
<td>$10.91</td>
<td>48%</td>
</tr>
<tr>
<td>Cactus (WHD)</td>
<td>$56.62</td>
<td>$111.45</td>
<td>49.2%</td>
</tr>
<tr>
<td>BlackSky Technology (BKSY)</td>
<td>$34.76</td>
<td>$68.23</td>
<td>49.1%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$227.23</td>
<td>$444.25</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 140 只被低估美国股票的完整列表。</p>
<p>让我们更仔细地看看我们筛选出的几只股票。</p>
<h2>Travere Therapeutics (TVTX)</h2>
<p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物制药公司，专注于识别、开发和提供针对美国罕见肾脏和代谢疾病的疗法，市值为 42.6 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自创新疗法的开发和商业化，金额为 5.362 亿美元。</p>
<p><strong>公允价值折扣估计：</strong> 46.6%</p>
<p>根据现金流分析，Travere Therapeutics 似乎被低估，当前交易价格为 45.81 美元，而未来现金流价值估计为 85.85 美元。尽管近期内部人士出售股票和股价波动，该公司显示出强劲的收入增长潜力，年增长率为 22.4%，超过市场的 11.8%。最近 FDA 批准 FILSPARI 用于治疗 FSGS，显著扩大了其可服务市场，可能增强未来三年的现金流和盈利能力预期。</p>
<ul>
<li>我们在 Travere Therapeutics 增长报告中详细分析的内容暗示了未来强劲的财务表现。</li>
<li>在这份财务健康报告中解锁我们对 Travere Therapeutics 股票分析的全面见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 6 月的 TVTX 折现现金流</p>
<h2>Goosehead Insurance (GSHD)</h2>
<p><strong>概述：</strong> Goosehead Insurance, Inc.作为 Goosehead Financial, LLC 的控股公司，在美国提供个人保险代理服务，市值约为 13.7 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其保险分销部门，产生了 3.822 亿美元的收入。</p>
<p><strong>公允价值折扣估计：</strong> 42%</p>
<p>Goosehead Insurance 的交易价格为 38.35 美元，低于其未来现金流价值估计的 66.13 美元，表明被低估。该公司报告 2026 年第一季度收入为 9308 万美元，净收入为 489 万美元，反映出强劲的财务表现，盈利增长年率为 21.7%，超过市场的 16.8%。尽管债务水平较高且股东权益为负，但总计 1.3151 亿美元的股票回购可能会增强未来的股东价值。</p>
<ul>
<li>我们的综合增长报告提出了 Goosehead Insurance 有望实现显著财务增长的可能性。</li>
<li>在这里深入了解 Goosehead Insurance 的完整分析健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 6 月的 GSHD 折现现金流</p>
<h2>National Bank Holdings (NBHC)</h2>
<p><strong>概述：</strong> National Bank Holdings Corporation，市值为 18.9 亿美元，作为 NBH Bank 的银行控股公司，向美国的商业、企业和消费者客户提供一系列银行产品和金融服务。</p>
<p><strong>运营：</strong> 公司的收入主要来自其银行部门，产生了 4.2918 亿美元的收入。</p>
<p><strong>公允价值折扣估计：</strong> 21.2%</p>
<p>National Bank Holdings 的交易价格为 42.19 美元，低于其估计的未来现金流价值 53.51 美元，表明其被低估超过 20%。预计该公司的收益将显著增长，年增长率为 30.7%，超过美国市场平均水平。最近的财务数据显示，2026 年第一季度净利息收入增加至 1.088 亿美元，尽管净收入较去年下降至 2079 万美元。最近回购价值 1611 万美元的股票可能会支持股东价值，尽管过去存在稀释担忧。</p>
<ul>
<li>我们的收益增长报告揭示了 National Bank Holdings 未来业绩显著增长的潜力。</li>
<li>在这里通过我们的综合财务健康报告深入了解 National Bank Holdings 的复杂情况。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 6 月的 NBHC 折现现金流</p>
<h2>总结</h2>
<ul>
<li>通过使用我们的筛选器，深入了解所有 140 只基于现金流的被低估美国股票。</li>
<li>拥有这些公司的股份？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>使用 Simply Wall St 的应用程序简化您的投资策略，免费获取全球各地股票的广泛研究。</li>
</ul>
<h2>准备好尝试不同的方法了吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健分红支付者来多样化您的投资组合，以应对潜在的市场动荡。</li>
<li>通过分析师和管理层的乐观展望，推动您的投资组合中显示出强劲增长潜力的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您所有的股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

SOLS

NBHC

TVTX

拉美商业服务

鹅头保险

KMLI

<p>Simply Wall St 根据现金流分析识别出到 2026 年 6 月可能被低估的美国股票。推荐的股票包括 Travere Therapeutics (TVTX)、Goosehead Insurance (GSHD) 和 National Bank Holdings (NBHC)，这些股票的交易价格均低于估计的公允价值，并且预计有强劲的盈利增长。文章还列出了其他一些被低估的优质股票，如 Solstice Advanced Materials 和 MercadoLibre，建议在市场波动中寻找投资机会</p>

<p>Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.</p>
<div class="lb-trans"><p>在过去的 7 天里，美国市场下跌了 2.5%，但在过去一年中上涨了 23%，预计未来几年收益将以每年 17% 的速度增长。在这种环境下，识别可能低于其估计价值的股票可以为寻求利用未来增长前景的投资者提供潜在机会。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3>
<div class="lb-trans"><h3>基于现金流的美国十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Solstice Advanced Materials (SOLS)</td>
<td>$81.02</td>
<td>$156.32</td>
<td>48.2%</td>
</tr>
<tr>
<td>Robert Half (RHI)</td>
<td>$31.26</td>
<td>$60.09</td>
<td>48%</td>
</tr>
<tr>
<td>Rayonier (RYN)</td>
<td>$20.97</td>
<td>$40.79</td>
<td>48.6%</td>
</tr>
<tr>
<td>MercadoLibre (MELI)</td>
<td>$1607.80</td>
<td>$3085.44</td>
<td>47.9%</td>
</tr>
<tr>
<td>Live Oak Bancshares (LOB)</td>
<td>$37.41</td>
<td>$74.21</td>
<td>49.6%</td>
</tr>
<tr>
<td>Lazard (LAZ)</td>
<td>$46.36</td>
<td>$91.21</td>
<td>49.2%</td>
</tr>
<tr>
<td>Inter &amp; Co (INTR)</td>
<td>$5.67</td>
<td>$10.91</td>
<td>48%</td>
</tr>
<tr>
<td>Cactus (WHD)</td>
<td>$56.62</td>
<td>$111.45</td>
<td>49.2%</td>
</tr>
<tr>
<td>BlackSky Technology (BKSY)</td>
<td>$34.76</td>
<td>$68.23</td>
<td>49.1%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$227.23</td>
<td>$444.25</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>Solstice Advanced Materials (SOLS)</td>
<td>$81.02</td>
<td>$156.32</td>
<td>48.2%</td>
</tr>
<tr>
<td>Robert Half (RHI)</td>
<td>$31.26</td>
<td>$60.09</td>
<td>48%</td>
</tr>
<tr>
<td>Rayonier (RYN)</td>
<td>$20.97</td>
<td>$40.79</td>
<td>48.6%</td>
</tr>
<tr>
<td>MercadoLibre (MELI)</td>
<td>$1607.80</td>
<td>$3085.44</td>
<td>47.9%</td>
</tr>
<tr>
<td>Live Oak Bancshares (LOB)</td>
<td>$37.41</td>
<td>$74.21</td>
<td>49.6%</td>
</tr>
<tr>
<td>Lazard (LAZ)</td>
<td>$46.36</td>
<td>$91.21</td>
<td>49.2%</td>
</tr>
<tr>
<td>Inter &amp; Co (INTR)</td>
<td>$5.67</td>
<td>$10.91</td>
<td>48%</td>
</tr>
<tr>
<td>Cactus (WHD)</td>
<td>$56.62</td>
<td>$111.45</td>
<td>49.2%</td>
</tr>
<tr>
<td>BlackSky Technology (BKSY)</td>
<td>$34.76</td>
<td>$68.23</td>
<td>49.1%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$227.23</td>
<td>$444.25</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 140 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 140 只被低估美国股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>让我们更仔细地看看我们筛选出的几只股票。</p>
</div><h2>Travere Therapeutics (TVTX)</h2>
<div class="lb-trans"><h2>Travere Therapeutics (TVTX)</h2>
</div><p><strong>Overview:</strong> Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $4.26 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物制药公司，专注于识别、开发和提供针对美国罕见肾脏和代谢疾病的疗法，市值为 42.6 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the development and commercialization of innovative therapies, amounting to $536.20 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自创新疗法的开发和商业化，金额为 5.362 亿美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 46.6%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 46.6%</p>
</div><p>Travere Therapeutics appears undervalued based on cash flow analysis, trading at US$45.81 compared to a future cash flow value estimate of US$85.85. Despite recent insider selling and share price volatility, the company shows strong revenue growth potential at 22.4% annually, outpacing the market's 11.8%. Recent FDA approval for FILSPARI in treating FSGS expands its addressable market significantly, potentially enhancing future cash flows and profitability projections over the next three years.</p>
<div class="lb-trans"><p>根据现金流分析，Travere Therapeutics 似乎被低估，当前交易价格为 45.81 美元，而未来现金流价值估计为 85.85 美元。尽管近期内部人士出售股票和股价波动，该公司显示出强劲的收入增长潜力，年增长率为 22.4%，超过市场的 11.8%。最近 FDA 批准 FILSPARI 用于治疗 FSGS，显著扩大了其可服务市场，可能增强未来三年的现金流和盈利能力预期。</p>
</div><ul>
<li>The analysis detailed in our Travere Therapeutics growth report hints at robust future financial performance.</li>
<li>Unlock comprehensive insights into our analysis of Travere Therapeutics stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们在 Travere Therapeutics 增长报告中详细分析的内容暗示了未来强劲的财务表现。</li>
<li>在这份财务健康报告中解锁我们对 Travere Therapeutics 股票分析的全面见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf?theme=light"/></p>
<p>TVTX Discounted Cash Flow as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 TVTX 折现现金流</p>
</div><h2>Goosehead Insurance (GSHD)</h2>
<div class="lb-trans"><h2>Goosehead Insurance (GSHD)</h2>
</div><p><strong>Overview:</strong> Goosehead Insurance, Inc. operates as a holding company for Goosehead Financial, LLC, offering personal lines insurance agency services in the United States with a market cap of approximately $1.37 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Goosehead Insurance, Inc.作为 Goosehead Financial, LLC 的控股公司，在美国提供个人保险代理服务，市值约为 13.7 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its insurance distribution segment, which generated $382.20 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其保险分销部门，产生了 3.822 亿美元的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 42%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 42%</p>
</div><p>Goosehead Insurance is trading at US$38.35, below its future cash flow value estimate of US$66.13, suggesting undervaluation. The company reported Q1 2026 revenue of US$93.08 million and net income of US$4.89 million, reflecting strong financial performance with earnings growth outpacing the market at 21.7% annually versus 16.8%. Despite high debt levels and negative equity, significant share buybacks totaling US$131.51 million may enhance shareholder value moving forward.</p>
<div class="lb-trans"><p>Goosehead Insurance 的交易价格为 38.35 美元，低于其未来现金流价值估计的 66.13 美元，表明被低估。该公司报告 2026 年第一季度收入为 9308 万美元，净收入为 489 万美元，反映出强劲的财务表现，盈利增长年率为 21.7%，超过市场的 16.8%。尽管债务水平较高且股东权益为负，但总计 1.3151 亿美元的股票回购可能会增强未来的股东价值。</p>
</div><ul>
<li>Our comprehensive growth report raises the possibility that Goosehead Insurance is poised for substantial financial growth.</li>
<li>Delve into the full analysis health report here for a deeper understanding of Goosehead Insurance.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的综合增长报告提出了 Goosehead Insurance 有望实现显著财务增长的可能性。</li>
<li>在这里深入了解 Goosehead Insurance 的完整分析健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf?theme=light"/></p>
<p>GSHD Discounted Cash Flow as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 GSHD 折现现金流</p>
</div><h2>National Bank Holdings (NBHC)</h2>
<div class="lb-trans"><h2>National Bank Holdings (NBHC)</h2>
</div><p><strong>Overview:</strong> National Bank Holdings Corporation, with a market cap of $1.89 billion, operates as the bank holding company for NBH Bank, offering a range of banking products and financial services to commercial, business, and consumer clients in the United States.</p>
<div class="lb-trans"><p><strong>概述：</strong> National Bank Holdings Corporation，市值为 18.9 亿美元，作为 NBH Bank 的银行控股公司，向美国的商业、企业和消费者客户提供一系列银行产品和金融服务。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its banking segment, which generated $429.18 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其银行部门，产生了 4.2918 亿美元的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 21.2%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 21.2%</p>
</div><p>National Bank Holdings is trading at US$42.19, below its estimated future cash flow value of US$53.51, indicating it is undervalued by over 20%. The company's earnings are forecast to grow significantly at 30.7% annually, surpassing the US market average. Recent financials show net interest income increased to US$108.8 million in Q1 2026, though net income decreased to US$20.79 million from a year ago. A recent buyback of shares worth $16.11 million may support shareholder value despite past dilution concerns.</p>
<div class="lb-trans"><p>National Bank Holdings 的交易价格为 42.19 美元，低于其估计的未来现金流价值 53.51 美元，表明其被低估超过 20%。预计该公司的收益将显著增长，年增长率为 30.7%，超过美国市场平均水平。最近的财务数据显示，2026 年第一季度净利息收入增加至 1.088 亿美元，尽管净收入较去年下降至 2079 万美元。最近回购价值 1611 万美元的股票可能会支持股东价值，尽管过去存在稀释担忧。</p>
</div><ul>
<li>Our earnings growth report unveils the potential for significant increases in National Bank Holdings' future results.</li>
<li>Navigate through the intricacies of National Bank Holdings with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的收益增长报告揭示了 National Bank Holdings 未来业绩显著增长的潜力。</li>
<li>在这里通过我们的综合财务健康报告深入了解 National Bank Holdings 的复杂情况。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf?theme=light"/></p>
<p>NBHC Discounted Cash Flow as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 NBHC 折现现金流</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Get an in-depth perspective on all 140 Undervalued US Stocks Based On Cash Flows by using our screener here.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过使用我们的筛选器，深入了解所有 140 只基于现金流的被低估美国股票。</li>
<li>拥有这些公司的股份？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>使用 Simply Wall St 的应用程序简化您的投资策略，免费获取全球各地股票的广泛研究。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好尝试不同的方法了吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健分红支付者来多样化您的投资组合，以应对潜在的市场动荡。</li>
<li>通过分析师和管理层的乐观展望，推动您的投资组合中显示出强劲增长潜力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您所有的股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

三只股票可能在 2026 年 6 月的价格低于其预估价值